Alzheimer's Disease
IND-enabling studies underway
Two companion biologics that visualize Alzheimer's with accuracy and treat it at the source — unified by AI. Our published preclinical animal-model data show reversal of cogntive deficits.
Biologic A — Diagnostic
Accurately shows which brain regions are affected and how severely. Readily repeatable studies — No PET isotopes, no invasive procedures.
Biologic B — Treatment
Delivers a therapeutic protein directly and non-invasively to brain. Preclinical animal-model data show reversal of cognitive deficits.
Custom AI Platform
Tracks early warning signs, estimates personalized risk scores, and supports the treatment strategy in real time. Clinician decision support, fully documented.
The approach
Alzheimer's has two devastating problems: we can't see it coming clearly enough, and we can't stop it once it starts. ExQor tackles both simultaneously with a unified system.
The MRI diagnostic biologic reveals exactly where damage is occurring. That scan then drives the treatment — telling us precisely where to target, how much to give, and whether it's working. No guesswork, no population-level dosing.
"Approved antibody therapies such as lecanemab and donanemab are designed to slow progression. ExQor is pursuing a different goal — repair at the source — and our published preclinical animal-model data show reversal of cognitive deficits . Clinical efficacy in humans will be established in our clinical trials."
Both biologics use a clathrin-mediated transport mechanism to cross the blood-brain barrier non-invasively — a platform discovery that underpins the entire system.
Simplified administration. No surgery, no infusion center required — with home-based delivery potential.
MRI scans confirm treatment response over time. Objective evidence, not subjective reporting.
Further enhancing clinician decision support, the AI platform design is open to 3rd party AI systems, e.g., Anthropic, Open AI, Gemini AI. For controlling healthcare record security, the platform is open to development of local-only AI systems with open-source software (e.g., Qwen x.)
Development status
ExQor is in IND-enabling studies targeting Phase 1 first-in-human trials. Our regulatory strategy leverages the diagnostic biologic as the entry point under FDA's companion diagnostic framework, with the treatment biologic following in sequence.
Market & patient impact
For the approximately 55 million people worldwide living with dementia — and the 131.5 million projected by 2050 — ExQor's unified approach aims to shift the treatment paradigm from disease management toward disease modification and repair. This is the program's objective; it has not yet been demonstrated in humans.
MRI diagnostic accessibility and home-based delivery potential could democratize access to advanced neurological care, reducing the global economic burden currently projected to reach $1.6 trillion by 2050. (Source: The Lancet)
We welcome inquiries from partners interested in our CNS diagnostic and therapeutic programs.
Email: info@exqor.com
Tel: +1 (617) 742-4422